Researchers have demonstrated that breast cancer can resurface 15 years after treatment, epigenetic editing has revealed a surprising insight into early breast cancer development and two breakthrough CDK4/6-inhibitor drugs have been approved for advanced breast cancer.
Browsing: Taxonomy > Clinical trials
Find out about IMPACT, a partnership between Anthony Nolan, Leuka, NHS Blood and Transplant and the University of Birmingham (UK), which aims to deliver the UK’s first large-scale clinical trials program in this exclusive blog piece.
In this interview with the Vice President of Global Development at Amgen we take a more in-depth look at the trastuzumab data, an oncology biosimilar medicine.
In this interview discover further details of the JAVELIN Merkel 200 that led to the approval of the first immunotherapy treatment indicated in the EU and the first US FDA-approved systemic therapy for merkel cell carcinoma.
A novel ‘labyrinth’ chip is isolating cancer cells from the blood of patients with an aggressive form of breast cancer in a clinical trial.
What is the potential clinical significance of the results of the FLAURA trial presented at ESMO? Find out in our exclusive interview.
A nationwide study across Ireland revealed that the vast majority of patients do not understand the core concepts underpinning a clinical trial.
We spoke with a key study investigator of the multiple myeloma ENDEAVOR trial to explore the trial in more detail and to discover the potential clinical application of its overall survival findings.
Discover the economic burden of allogeneic hematopoietic stem cell transplant in acute lymphoblastic leukemia pediatric patients in this research article from our partnered journal, the International Journal of Hematologic Oncology.
Arndt Vogel (Hanover Medical University, Germany) provides insight on the recent noninferiority REFLECT trial with lenvatinib vs sorafenib in unresectable hepatocellular carcinoma.